Jim Simons’s Theravance Biopharma TBPH Stock Holding History

Jim Simons’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.08M	Buy	+127,916	New	+$2.26M	﹤0.01%	1877
2023 Q1	–	Sell	-176,426	Closed	-$1.98M	–	4394
2022 Q4	$1.98M	Buy	176,426 +24,249	+16%	+$255K	﹤0.01%	2077
2022 Q3	$1.54M	Buy	+152,177	New	+$1.43M	﹤0.01%	2209
2020 Q1	–	Sell	-17,003	Closed	-$440K	–	3780
2019 Q4	$440K	Buy	+17,003	New	+$330K	﹤0.01%	2951
2018 Q2	–	Sell	-40,300	Closed	-$977K	–	3524
2018 Q1	$977K	Buy	+40,300	New	+$1.11M	﹤0.01%	2669
2016 Q1	–	Sell	-10,880	Closed	-$178K	–	3523
2015 Q4	$178K	Buy	+10,880	New	+$173K	﹤0.01%	3024
2015 Q3	–	Sell	-263,816	Closed	-$3.44M	–	3358
2015 Q2	$3.44M	Buy	+263,816	New	+$4.09M	0.01%	1688
2015 Q1	–	Sell	-14,086	Closed	-$210K	–	3340
2014 Q4	$210K	Buy	+14,086	New	+$245K	﹤0.01%	2683

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jim Simons's TBPH Position: Q1 2026 in Review

Jim Simons opened a new position in Theravance Biopharma (TBPH) in Q1 2026: 127,916 shares worth $2.08M. The stake represents ﹤0.01% of the portfolio and ranks #1877 among its holdings. This is a return to the name: Jim Simons previously reported a position in TBPH as recently as Q4 2022.

Jim Simons first reported a position in TBPH in Q4 2014 and has held it in 8 quarters since. The position peaked at $3.44M in Q2 2015. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

Jim Simons held 127,916 shares of Theravance Biopharma worth $2.08M as of Q1 2026.
Theravance Biopharma was a new Jim Simons position in Q1 2026.
Theravance Biopharma made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1877 holding.
Jim Simons first reported a position in Theravance Biopharma in Q4 2014 and has held it in 8 quarters since.
Jim Simons's Theravance Biopharma position peaked at $3.44M in Q2 2015.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.